JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC
(2026) Future Oncology — Vol. 22, n° 3, p. 313-320 (2026)
Files
IFON_22_2619653.pdf
Open Access - Adobe PDF
- 378.93 KB
Details
- Authors
- Abstract
- Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 5% of cancer cases worldwide, with more than half of patients presenting with locally advanced (LA) disease. Treatment of LA HNSCC is multimodal and may include concomitant cisplatin-based chemoradiotherapy (CRT) or surgery; however, recurrence rates are high, and there is an unmet need for new treatments. Immune checkpoint inhibitors that target programmed death receptor-1 (PD-1) are standard of care for recurrent/metastatic HNSCC, but outcomes for anti-PD-1 and anti-PD-(ligand [L])1 therapies with CRT in LA HNSCC have been variable. Dostarlimab, an anti-PD-1 therapy approved in advanced endometrial cancer and mismatch repair-deficient solid tumors is being investigated across other tumor types, including HNSCC. JADE is a global, multicenter, double-blind, placebo-controlled, randomized phase 3 study evaluating the efficacy and safety of dostarlimab as post-cisplatin-based CRT sequential therapy in patients with LA unresected PD-L1-expressing HNSCC. JADE seeks to overcome the limitations of previous studies by incorporating both PD-L1 selection and solely sequential administration of dostarlimab soon after CRT.
- Affiliations
Citations
Siu, L. L., Burtness, B., Harrington, K., Psyrri, A., Saba, N. F., Tahara, M., Carlson, G., Dhar, A., Grimshaw, M., Hua, L., Iadevaia, R., Theti, D., Vlahovic, G., & Machiels, J.-P. (2026). JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC. Future Oncology, 22(3), 313-320. https://doi.org/10.1080/14796694.2026.2619653 (Original work published 2026)